摘要
HIV-1 基质蛋白P17在病毒生命周期中起着重要作用。它是从HIV-1感染细胞的外空间释放并在患者组织中积累,甚至对那些利用高活性抗逆转录病毒疗法成功治疗的患者也是如此。细胞外P17抑制许多直接或间接与艾滋病相关的细胞生物学功能。所有P17活动都取决于位于蛋白质N端的功能表位和表达于靶细胞上的不同受体之间的相互作用。这些发现表明了阻碍p17和p17受体之间的相互作用对阻断AIDS的重要性。本文讨论了P17与硫酸乙酰肝素蛋白多糖(HSPGs),以及与趋化因子(CXC)受体1(CXCR1)和受体2(CXCR2)之间的相互作用。我们对P17如何与其受体相互作用、这些相互作用如何成为P17生物活性中心进行了阐述。此外,我们发现了P17变种的存在、并命名为s75x,与P17相比,s75x对B细胞增殖有着相反的作用。P17与G蛋白偶联受体相互作用的二位点模型为自然发生在原发性氨基酸结构中的突变为什么能促使s75x激活Akt信号通路、促进B细胞生长和转化提供了合理的解释。P17与HSPGs、CXCR1和CXCR2细胞相互作用的识别将有助于寻找阻断所有p17和p17相互作用以及p17有害影响的治疗方法。
关键词: HIV-1,基质蛋白p17,CXCR1、CXCR2,硫酸乙酰肝素蛋白多糖,信号通路,治疗疫苗,CXCR1单倍型
图形摘要
Current Drug Targets
Title:HIV-1 Matrix Protein p17 and its Receptors
Volume: 17 Issue: 1
Author(s): Francesca Caccuri, Stefania Marsico, Simona Fiorentini, Arnaldo Caruso and Cinzia Giagulli
Affiliation:
关键词: HIV-1,基质蛋白p17,CXCR1、CXCR2,硫酸乙酰肝素蛋白多糖,信号通路,治疗疫苗,CXCR1单倍型
摘要: The HIV-1 matrix protein p17 (p17) plays a crucial role in the virus life cycle. It is released in the extracellular space from HIV-1-infected cells and accumulates in the tissues of patients, even in those successfully treated with highly active antiretroviral therapy. Extracellular p17 deregulates the biological functions of many different cells that are directly or indirectly implicated in AIDS pathogenesis. All p17 actions depend on interaction between its functional epitope (AT20), located at the protein N-terminal region, and different receptors expressed on target cells. This finding corroborates the importance of impeding p17/p17 receptors interaction as a contribution to block AIDS. In this article we review the interaction of p17 with heparan sulfate proteoglycans (HSPGs) and with the chemokine (C-X-C motif) receptor 1 (CXCR1) and 2 (CXCR2). We provide details on how p17 interacts with its receptors and how these interactions are central to the p17 biological activities. Moreover, we highlight the existence of a p17 variant, named S75X, which displays opposite effects on B-cell proliferation as compared to p17. A two-site model for p17 interaction with G-coupled receptors provides a possible explanation on how mutations naturally occurring within the primary amino acid structure can lead S75X to activate the Akt signaling pathway and to promote B-cell growth and transformation. Identification of p17 interaction with HSPGs, CXCR1 and CXCR2 as a fundamental event in supporting its activity could help to find new treatment approaches aimed at blocking all p17/p17 receptors interactions and, consequently, p17 detrimental activities.
Export Options
About this article
Cite this article as:
Francesca Caccuri, Stefania Marsico, Simona Fiorentini, Arnaldo Caruso and Cinzia Giagulli , HIV-1 Matrix Protein p17 and its Receptors, Current Drug Targets 2016; 17 (1) . https://dx.doi.org/10.2174/1389450116666150825110840
DOI https://dx.doi.org/10.2174/1389450116666150825110840 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Prospects for Nelfinavir in Non-HIV-Related Diseases
Current Molecular Pharmacology Identification of Novel 5,6-Dimethoxyindan-1-one Derivatives as Antiviral Agents
Medicinal Chemistry Silver Based Materials for Biomedical Applications
Current Organic Chemistry Monoclonal Antibodies as Innovative Therapeutics
Current Pharmaceutical Biotechnology Antiplatelet and Antileukocyte Effects of Cardiovascular,Immunomodulatory and Chemotherapeutic Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of PPARβ/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Prediction of Cancer Rescue p53 Mutants In Silico Using Naïve Bayes Learning Methodology
Protein & Peptide Letters Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity
Current Topics in Medicinal Chemistry The Antitumoral Mode of Action of Imiquimod and Other Imidazoquinolines
Current Medicinal Chemistry Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Targeting of Apoptotic Pathways in Cancer
Current Drug Targets Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View
Current Cancer Drug Targets From Bortezomib to other Inhibitors of the Proteasome and Beyond
Current Pharmaceutical Design Recent Advances in Immune Modulation
Current Gene Therapy RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry Bombacaceae Between the Ethnomedical Uses and Pharmacological Evidences: A Review
The Natural Products Journal Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Signaling Pathways Underpinning the Manifestations of Ionizing Radiation-Induced Bystander Effects
Current Molecular Pharmacology